Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
Primary Purpose
Uterine Fibroids
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Uterine Fibroid Embolization
Sponsored by
About this trial
This is an interventional treatment trial for Uterine Fibroids focused on measuring Uterine Fibroids, Embolization
Eligibility Criteria
Inclusion Criteria:
- She is able to provide informed consent and sign the Institutional Review Board approved informed consent form.
- She is pre-menopausal and 30-50 years of age at the time of enrollment.
- She is not actively attempting to become pregnant for a minimum of 1 year after UFE, or practicing abstinence and willing to continue for a minimum of 1 year after UFE, or is surgically sterile.
- She is suffering from clinically significant symptoms attributed to the presence of uterine fibroids including abnormal menstrual bleeding and/or bulk-related symptoms including pelvic pain/discomfort, abdominal distension, urinary symptoms (including but not limited to increased urinary frequency or urinary hesitancy), and/or dyspareunia.
Exclusion Criteria:
- She has a history of pelvic malignancy.
- She is pregnant or intends to become pregnant within 12 months of the planned UFE procedure.
- She has had an abnormal PAP smear (anything other than normal or ASCUS - Atypical Squamous Cells of Unknown Significance) within 12 months of the planned UFE procedure.
- She has a coexisting condition that might explain the presenting symptoms (including but not limited to adenomyosis, endometrial hyperplasia, endometriosis, and complex ovarian cysts).
- She has evidence of current or recent pelvic inflammatory disease or uterine infection.
- She has another serious medical condition that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, etc.)
- She has a severe contrast allergy or renal insufficiency that would represent a contraindication to the administration of iodine-based or gadolinium-based contrast agents.
- She has a contraindication to magnetic resonance imaging (MRI).
- She has one or more MRI findings including a uterine size >20 cm in greatest length, a dominant fibroid with a greatest diameter >12 cm, an intracavitary submucosal fibroid, or non enhancing dominant fibroids.
- In the judgment of the investigator, she is unable or unlikely to be able to comply with the study procedures and requirements.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Embozene Microspheres
Embosphere Microspheres
Arm Description
Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
Outcomes
Primary Outcome Measures
Fibroid Infarction Rate
The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is >90% as seen on contrast-enhanced MRI.
Secondary Outcome Measures
Symptom Severity
The percentage of patients experiencing improvement in symptom severity after the uterine fibroid embolization procedure.
Health-Related Quality of Life
The percentage of patients experiencing improvement in health-related quality of life after the uterine fibroid embolization procedure.
Uterine Volume
The change in uterine volume as seen on MRI examinations performed 3 months after the embolization procedure.
Dominant Fibroid Volume
The change in dominant fibroid volume as seen on MRI examinations performed 3 months after the embolization procedure.
Frequency of Adverse Events After Treatment
The frequency of adverse events occurring after embolization will be monitored and reported.
Full Information
NCT ID
NCT02884960
First Posted
August 26, 2016
Last Updated
August 30, 2016
Sponsor
Gary Siskin, MD
Collaborators
Boston Scientific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02884960
Brief Title
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
Official Title
Safety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief From Uterine Fibroids
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
October 2017 (Anticipated)
Study Completion Date
October 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gary Siskin, MD
Collaborators
Boston Scientific Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids. A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. Symptom severity, health-related quality of life, and the appearance of the fibroids will be assessed prior to treatment. Patients will then undergo the uterine fibroid embolization procedure with either Embosphere Microspheres or Embozene Microspheres, which will be randomly assigned. Clinical outcomes will be assessed 1 month, 3 months, 6 months and 12 months after the procedure, and imaging outcomes will be obtained 3 months after the procedure.
Detailed Description
The uterine fibroid embolization (UFE) procedure is an accepted, minimally invasive treatment option for patients with symptomatic uterine fibroids. Studies evaluating the outcomes after this procedure have established that the use of polyvinyl alcohol particles and Embosphere Microspheres is associated with best clinical and imaging outcomes. Embozene Microspheres represent a new embolic agent that is being evaluated for use for the treatment of symptomatic fibroids. The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids.
A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. A questionnaire designed to assess symptom severity and health-related quality of life in patients will be administered to patients at the time of enrollment. In addition, a contrast-enhanced magnetic resonance imaging (MRI) examination will be performed to confirm the diagnosis of fibroids. Patients will then undergo the uterine fibroid embolization procedure. The embolic agent used for the procedure (Embosphere Microspheres or Embozene Microspheres) will be randomly assigned. Patients will be seen 1 month, 3 months, and 6 months and contacted 12 months after the procedure so that the same questionnaire can be used to assess clinical outcomes. In addition, an MRI will be performed 3 months after the procedure to determine the imaging response to treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroids
Keywords
Uterine Fibroids, Embolization
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
118 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Embozene Microspheres
Arm Type
Experimental
Arm Description
Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
Arm Title
Embosphere Microspheres
Arm Type
Active Comparator
Arm Description
Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
Intervention Type
Procedure
Intervention Name(s)
Uterine Fibroid Embolization
Intervention Description
This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
Primary Outcome Measure Information:
Title
Fibroid Infarction Rate
Description
The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is >90% as seen on contrast-enhanced MRI.
Time Frame
3 Months
Secondary Outcome Measure Information:
Title
Symptom Severity
Description
The percentage of patients experiencing improvement in symptom severity after the uterine fibroid embolization procedure.
Time Frame
12 Months
Title
Health-Related Quality of Life
Description
The percentage of patients experiencing improvement in health-related quality of life after the uterine fibroid embolization procedure.
Time Frame
12 Months
Title
Uterine Volume
Description
The change in uterine volume as seen on MRI examinations performed 3 months after the embolization procedure.
Time Frame
3 Months
Title
Dominant Fibroid Volume
Description
The change in dominant fibroid volume as seen on MRI examinations performed 3 months after the embolization procedure.
Time Frame
12 Months
Title
Frequency of Adverse Events After Treatment
Description
The frequency of adverse events occurring after embolization will be monitored and reported.
Time Frame
12 Months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
She is able to provide informed consent and sign the Institutional Review Board approved informed consent form.
She is pre-menopausal and 30-50 years of age at the time of enrollment.
She is not actively attempting to become pregnant for a minimum of 1 year after UFE, or practicing abstinence and willing to continue for a minimum of 1 year after UFE, or is surgically sterile.
She is suffering from clinically significant symptoms attributed to the presence of uterine fibroids including abnormal menstrual bleeding and/or bulk-related symptoms including pelvic pain/discomfort, abdominal distension, urinary symptoms (including but not limited to increased urinary frequency or urinary hesitancy), and/or dyspareunia.
Exclusion Criteria:
She has a history of pelvic malignancy.
She is pregnant or intends to become pregnant within 12 months of the planned UFE procedure.
She has had an abnormal PAP smear (anything other than normal or ASCUS - Atypical Squamous Cells of Unknown Significance) within 12 months of the planned UFE procedure.
She has a coexisting condition that might explain the presenting symptoms (including but not limited to adenomyosis, endometrial hyperplasia, endometriosis, and complex ovarian cysts).
She has evidence of current or recent pelvic inflammatory disease or uterine infection.
She has another serious medical condition that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, etc.)
She has a severe contrast allergy or renal insufficiency that would represent a contraindication to the administration of iodine-based or gadolinium-based contrast agents.
She has a contraindication to magnetic resonance imaging (MRI).
She has one or more MRI findings including a uterine size >20 cm in greatest length, a dominant fibroid with a greatest diameter >12 cm, an intracavitary submucosal fibroid, or non enhancing dominant fibroids.
In the judgment of the investigator, she is unable or unlikely to be able to comply with the study procedures and requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Barbara MacDowell
Phone
518-262-5149
Email
macdowb@mail.amc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gary Siskin, MD
Organizational Affiliation
Community Care Physicians
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
We'll reach out to this number within 24 hrs